gip and glp 1 receptor agonist Tirzepatide's Unique Mechanism of Action LY3437943, a novel triple glucagon,

EBioMedicine 93 , 104642 (2023)

Patients currently using compounded semaglutide or tirzepatide should discuss transitioning to FDA approved formulations with their healthcare provider

But there was no link between GLP-1RAs and an increased risk of cancer overall in a meta-analysis that included 37 relevant multiple dose-escalation

The popularity of Wegovy (and off-label use of Ozempic for weight loss) skyrocketed, leading to periodic shortages of semaglutide products in 20222023 ( [14] )

Conclusions GLP1-RA reduce the risk of MACE by 14% in eight CVOTs with 60,080 patients with T2DM over a period ranging from 1.3 to 5.4 years